Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Patients With Severe Hemophilia A
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Sponsors Octapharma
- 08 Oct 2019 According to an Octapharma media release, based on the results of this trial, the U.S. Food and Drug Administration (FDA) has approved WILATE for the treatment of adults and adolescents with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes and on demand treatment and control of bleeding episodes.
- 17 Apr 2018 Status changed from active, no longer recruiting to completed.
- 12 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.